Literature DB >> 28860126

Incidence, Demographics, and Clinical Characteristics of Diabetes of the Exocrine Pancreas (Type 3c): A Retrospective Cohort Study.

Chris Woodmansey1, Andrew P McGovern1, Katherine A McCullough1,2, Martin B Whyte1,2, Neil M Munro1, Ana C Correa1, Piers A C Gatenby1,3, Simon A Jones1,4, Simon de Lusignan5,6.   

Abstract

OBJECTIVE: This study was conducted to describe the incidence of diabetes following pancreatic disease, assess how these patients are classified by clinicians, and compare clinical characteristics with type 1 and type 2 diabetes. RESEARCH DESIGN AND METHODS: Primary care records in England (n = 2,360,631) were searched for incident cases of adult-onset diabetes between 1 January 2005 and 31 March 2016. We examined demographics, diabetes classification, glycemic control, and insulin use in those with and without pancreatic disease (subcategorized into acute pancreatitis or chronic pancreatic disease) before diabetes diagnosis. Regression analysis was used to control for baseline potential risk factors for poor glycemic control (HbA1c ≥7% [53 mmol/mol]) and insulin requirement.
RESULTS: We identified 31,789 new diagnoses of adult-onset diabetes. Diabetes following pancreatic disease (2.59 [95% CI 2.38-2.81] per 100,000 person-years) was more common than type 1 diabetes (1.64 [1.47-1.82]; P < 0.001). The 559 cases of diabetes following pancreatic disease were mostly classified by clinicians as type 2 diabetes (87.8%) and uncommonly as diabetes of the exocrine pancreas (2.7%). Diabetes following pancreatic disease was diagnosed at a median age of 59 years and BMI of 29.2 kg/m2. Diabetes following pancreatic disease was associated with poor glycemic control (adjusted odds ratio, 1.7 [1.3-2.2]; P < 0.001) compared with type 2 diabetes. Insulin use within 5 years was 4.1% (3.8-4.4) with type 2 diabetes, 20.9% (14.6-28.9) with diabetes following acute pancreatitis, and 45.8% (34.2-57.9) with diabetes following chronic pancreatic disease.
CONCLUSIONS: Diabetes of the exocrine pancreas is frequently labeled type 2 diabetes but has worse glycemic control and a markedly greater requirement for insulin.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28860126     DOI: 10.2337/dc17-0542

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  49 in total

1.  Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer-Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study.

Authors:  Jaelim Cho; Robert Scragg; Stephen J Pandol; Mark O Goodarzi; Maxim S Petrov
Journal:  Diabetes Care       Date:  2019-06-21       Impact factor: 19.112

2.  Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood.

Authors:  Cole D Bendor; Aya Bardugo; Inbar Zucker; Tali Cukierman-Yaffe; Miri Lutski; Estela Derazne; Tammy Shohat; Ofri Mosenzon; Dorit Tzur; Ari Sapir; Orit Pinhas-Hamiel; Richard G Kibbey; Itamar Raz; Arnon Afek; Hertzel C Gerstein; Amir Tirosh; Gilad Twig
Journal:  Diabetes Care       Date:  2019-11-06       Impact factor: 19.112

3.  Implications of Integrated Pancreatic Microcirculation: Crosstalk between Endocrine and Exocrine Compartments.

Authors:  Michael P Dybala; Lisa R Gebien; Megan E Reyna; Yolanda Yu; Manami Hara
Journal:  Diabetes       Date:  2020-11-04       Impact factor: 9.461

4.  Comparison of CGM-Derived Measures of Glycemic Variability Between Pancreatogenic Diabetes and Type 2 Diabetes Mellitus.

Authors:  Channabasappa Shivaprasad; Yalamanchi Aiswarya; Shah Kejal; Atluri Sridevi; Biswas Anupam; Barure Ramdas; Kolla Gautham; Premchander Aarudhra
Journal:  J Diabetes Sci Technol       Date:  2019-07-07

5.  Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Authors:  Phil A Hart; Dana K Andersen; Kieren J Mather; Alicia C Castonguay; Mandeep Bajaj; Melena D Bellin; David Bradley; Noemy Contreras; Aida Habtezion; Murray Korc; Yogish Kudva; Maxim S Petrov; David C Whitcomb; Dhiraj Yadav; Ying Yuan; Jo Ann S Rinaudo; Sudhir Srivastava; Jose Serrano; Mark O Goodarzi
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

6.  PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies: Rationale and Study Design for PROCEED From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Authors:  Dhiraj Yadav; Walter G Park; Evan L Fogel; Liang Li; Suresh T Chari; Ziding Feng; William E Fisher; Christopher E Forsmark; Christie Y Jeon; Aida Habtezion; Phil A Hart; Steven J Hughes; Mohamed O Othman; Jo Ann S Rinaudo; Stephen J Pandol; Temel Tirkes; Jose Serrano; Sudhir Srivastava; Stephen K Van Den Eeden; David C Whitcomb; Mark Topazian; Darwin L Conwell
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

Review 7.  Use of human islets to understand islet biology and diabetes: progress, challenges and suggestions.

Authors:  Nathaniel J Hart; Alvin C Powers
Journal:  Diabetologia       Date:  2018-12-14       Impact factor: 10.122

Review 8.  Tobacco and alcohol as risk factors for pancreatic cancer.

Authors:  Murray Korc; Christie Y Jeon; Mouad Edderkaoui; Stephen J Pandol; Maxim S Petrov
Journal:  Best Pract Res Clin Gastroenterol       Date:  2017-09-06       Impact factor: 3.043

9.  Identification of a Risk Profile for New-Onset Diabetes After Acute Pancreatitis.

Authors:  Stephen A Firkins; Phil A Hart; Georgios I Papachristou; Luis F Lara; Zobeida Cruz-Monserrate; Alice Hinton; Darwin L Conwell; David P Bradley; Somashekar G Krishna
Journal:  Pancreas       Date:  2021 May-Jun 01       Impact factor: 3.327

Review 10.  Global epidemiology and holistic prevention of pancreatitis.

Authors:  Maxim S Petrov; Dhiraj Yadav
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.